BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Targacept, Inc. (TRGT), AstraZeneca PLC (AZN) End Partnership on Failed Drug


5/1/2012 8:17:14 AM

One path to a billion-dollar drug discovery for Targacept Inc. officially closed Monday with the ending of its pharmaceutical collaboration on TC-5214 with AstraZeneca PLC. Targacept, an anchor tenant in Piedmont Triad Research Park, had been expecting AstraZeneca to terminate the TC-5214 licensing agreement. Last week, Targacept confirmed it would eliminate 65 jobs, or 46 percent of its workforce, in a restructuring following the failure of TC-5214 in four Phase 3 clinical trials for major depressive disorder. Targacept said other parts of its collaborative research and license agreement with AstraZeneca, which began in December 2005, remain in effect. The agreement focuses on cognitive disorders.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES